Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 14/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21604564 | 0.81 | OGA (0.70) | OGAOPRK1ADRA2BSLC6A4SLC6A3 | |
| SCHEMBL21604548 | 0.81 | OGA (0.70) | OGAOPRK1ADRA2BSLC6A4SLC6A3 | |
| SCHEMBL21605775 | 0.75 | ADRA2B (0.54) | OGAOPRK1ADRA2BSLC6A4SLC6A3 | |
| SCHEMBL21607972 | 0.75 | OGA (0.52) | OGAOPRK1ADRA2BSLC6A4SLC6A3 | |
| SCHEMBL21607817 | 0.74 | SIGMAR1 (0.54) | OGAOPRK1ADRA2BSLC6A4SLC6A3 | |
| SCHEMBL21608000 | 0.74 | OGA (0.51) | OGAOPRK1ADRA2BSLC6A4SLC6A3 | |
| SCHEMBL21607846 | 0.74 | ADRA2B (0.49) | OGAOPRK1ADRA2BSLC6A4SLC6A3 | |
| SCHEMBL21607996 | 0.74 | OGA (0.51) | OGAOPRK1ADRA2BSLC6A4SLC6A3 | |
| SCHEMBL29268279 | 0.73 | OGA (0.46) | OGAOPRK1ADRA2BSLC6A4SLC6A3 | |
| SCHEMBL20281636 | 0.72 | OGA (0.51) | OGAOPRK1ADRA2BSLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-04-29 | — | — | US | disclosed |
| WO-2019243530-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019243528-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019243526-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122763-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | OGA 1/4885OPRK1 1977/4885ADRA2B 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.